Myriad Genetics’ stock plummeted 46% after a brutal Q2 earnings report—revenue fell 10.5% to $190.7M, missing estimates, and adjusted loss per share hit 25 cents, way worse than expected. They slashed their full-year revenue forecast by over 10%, now projecting $780M midpoint, signaling tougher times ahead. With stock down 53% year-to-date and trading far below its November peak, investors are rattled—this isn’t just another dip for the volatile stock; it’s a stark warning that even big names can face steep market backlash when expectations aren’t met.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
